Treatment of isografted 9L rat brain tumors with β-5-o-carboranyl-2'- deoxyuridine neutron capture therapy

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 725-730

  Schinazi, Raymond F ^a,b   Hurwitz, Selwyn J ^a,b   Liberman, Irina ^a,b   Juodawlkis, Amy S ^a,b   Tharnish, Phillip ^a,b   Shi, Junxing ^a,b   Liotta, Dennis C ^a   Coderre, Jeffrey A ^c   Olson, Jeffrey ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORON; DEOXYURIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CONCENTRATION (PARAMETERS); HUMAN; HUMAN CELL; MALE; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TISSUE LEVEL;

ANIMALS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; DEOXYURIDINE; HUMANS; MALE; RADIATION-SENSITIZING AGENTS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 0033975646     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Barth, R. F., Soloway, A. H., Fairchild, R. G., and Brugger, R. M. Boron neutron capture therapy for cancer: realities and prospects. Cancer (Phila.), 70: 2995-3007, 1992.
2. Chanana, A. D., Capala, J., Chadha, M., Coderre, J. A., Diaz, A. Z., Elowitz, E. H., Iwai, J., Joel, D. D., Liu, H. B., Ma, R., Pendzick, N., Peress, N. S., Shady, M. S., Slatkin, D. N., Tyson, G. W., and Wielopolski, L. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery (Baltim.), 44: 1182-1193, 1999.
3. Sauerwein, W., Moss, R., Hideghety, K., Stecher-Rasmusen, F., de Vries, M., Reulen, H-J., Gvtz, C., Paquis, F., Grochulla, K., Haselsberger, K., Wolbers, J., Rassow, J., Pignol, J. P., Watkins, P., Vroegindeweij, C., Ravensberg, K., Garbe, S., Wiestler, O. D., Turowski, B., Zanella, F., et al. Status report on the European clinical trial of BNCT at Petten. In: M. F. Hawthorne, K. Shelly, and R. J. Wiersema (eds.), Frontiers in Neutron Capture Therapy, in press. New York: Plenum Press, 2000.
4. Busse, P., Zamenhof, R., Madoc-Jones, H., Solares, G., Kiger, S., Riley, K., Chuang, C., Rogers, G., and Harling, O. Clinical follow-up of patients with melanoma of the extremity treated in a phase I boron neutron capture therapy protocol. In: B. Larsson, J. Crawford, and R. Weinreich (eds.), Advances in Neutron Capture Therapy: Volume 1, Medicine and Physics, pp. 60-64. Amsterdam: Elsevier, 1997.
5. Busse, P., Zamenhof, R., Harling, O., Kaplan, I., Kaplan, J., Chuang, C., Goorley, J., Kiger, W. S., Riley, K., Tang, L., Solares, G., and Palmer, M. BNCT for glioblastoma multiforme and intracranial metastatic melanoma: clinical results of the Harvard-Massachusetts Institute of Technology phase I trial. In: M. F. Hawthorne, K. Shelly, and R. J. Wiersema (eds.), Frontiers in Neutron Capture Therapy, in press. New York: Plenum Press, 2000.
6. Soloway, A., Tjarks, W., Barnum, B., Rong, F-G., Barth, R., Codogni, I., and Wilson, J. The chemistry of neutron capture therapy. Chem. Rev., 98: 1515-1562, 1998.
7. Mehta, S. C., and Lu, D. R. Targeted drug delivery for boron neutron capture therapy. Pharm. Res. (NY), 13: 344-351, 1996.
8. Schinazi, R. F., Goudgaon, N. M., Fulcrand, G., El Kattan, Y., Lesnikowski, Z., Ullas, G. V., Moravek, J., and Liotta, D. C. Cellular pharmacology and biological activity of 5-carboranyl-2′-deoxyuridine. Int. J. Radiat. Oncol. Biol. Phys., 28: 1113-1120, 1994.
9. Lunato, A. J., Wang, J., Woollard, J. E., Anisuzzaman, A. K., Ji, W., Rong, F. G., Ikeda, S., Soloway, A. H., Eriksson, S., Ives, D. H., Blue, T. E., and Tjarks, W. Synthesis of 5-(carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J. Med. Chem., 42: 3378-3389, 1999.
10. Hurwitz, S. J., Ma, L., Eleuteri, A., Wright, J., Moravek, J., and Schinazi, R. F. Cellular pharmacology of the D-and L-enantiomers of B-5-o-carboranyl-2′-deoxyuridine. Nucleosides Nucleotides, in press, 2000.
11. Jarugula, V. R., Schinazi, R. F., Fulcrand-El Kattan, G., Liotta, D. C., and Boudinot, F. D. Pharmacokinetics of 5-carboranyl-2′-deoxyuridine in rats. J. Pharm. Sci., 83: 1697-1699, 1994.
12. Barth, R. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol., 36: 91-102, 1998.
13. Coderre, J. A., Button, T. M., Micca, P. L., Fisher, C. D., Nawrocky, M. M., and Liu, H. B. Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int. J. Radiat. Oncol. Biol. Phys., 30: 643-652, 1994.
14. Liu, H. B., Joel, D. D., Slatkin, D. N., and Coderre, J. A. Improved apparatus for neutron capture therapy of rat brain tumors. Int. J. Radiat. Oncol. Biol. Phys., 28: 1167-1173, 1994.
15. Coderre, J. A., Morris, G. M., Micca, P. L., Fisher, C. D., and Ross, G. A. Comparative assessment of single-dose and fractionated boron neutron capture therapy [published erratum appears in Radiat. Res., 145: 388]. Radiat. Res., 144: 310-317, 1995.
16. Workman, P. Controversies in drug delivery to tumors of the brain. In: L. Domellof (ed.), Drug Delivery in Cancer Treatment III, pp. 1-50. Berlin: Springer Verlag, 1990.
17. Hurwitz, S. J., Coleman, C. N., Riese, N., Loeffler, J. S., Alexander, E., Buswell, L., Neben, T. Y., Shargel, L., and Kramer, R. A. Distribution of etanidzole into human brain tumors: implications for treating high grade gliomas. Int. J. Radiat. Oncol. Biol. Phys., 22: 573-576, 1992.
18. Coderre, J. A., and Morris, G. M. The radiation biology of boron neutron capture therapy. Radiat. Res., 151: 1-18, 1999.